MDP vs. ACB, SUGR, OGI, FIRE, EPI, ICC, RIV, LEAF, HLS, and RX
Should you be buying Medexus Pharmaceuticals stock or one of its competitors? The main competitors of Medexus Pharmaceuticals include Aurora Cannabis (ACB), SugarBud Craft Growers (SUGR), Organigram (OGI), Supreme Cannabis (FIRE), ESSA Pharma (EPI), ICC Labs (ICC), RIV Capital (RIV), Leaf Mobile (LEAF), HLS Therapeutics (HLS), and BioSyent (RX). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Medexus Pharmaceuticals vs. Its Competitors
Aurora Cannabis (TSE:ACB) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.
Aurora Cannabis currently has a consensus price target of C$8.75, indicating a potential upside of 27.00%. Medexus Pharmaceuticals has a consensus price target of C$5.49, indicating a potential upside of 85.39%. Given Medexus Pharmaceuticals' higher possible upside, analysts plainly believe Medexus Pharmaceuticals is more favorable than Aurora Cannabis.
Medexus Pharmaceuticals has a net margin of 3.25% compared to Aurora Cannabis' net margin of -22.55%. Medexus Pharmaceuticals' return on equity of 11.07% beat Aurora Cannabis' return on equity.
4.4% of Aurora Cannabis shares are held by institutional investors. Comparatively, 0.7% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Aurora Cannabis' average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.
Aurora Cannabis has a beta of 1.200512, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Medexus Pharmaceuticals has a beta of 2.548292, meaning that its stock price is 155% more volatile than the S&P 500.
Medexus Pharmaceuticals has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Medexus Pharmaceuticals beats Aurora Cannabis on 11 of the 15 factors compared between the two stocks.
Get Medexus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medexus Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:MDP) was last updated on 9/17/2025 by MarketBeat.com Staff
Free MDP Stock Alerts